Clinical trials: TACE
Hepatocellular Carcinoma (HCC), Real World Study
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has continuously brought breakthroughs in the treatment of hepatocellular carcinoma and has gradually become the cornerstone of advanced liver cancer treatment.
- Trial name
- NCT07078292
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Unresectable Hepatocellular Carcinoma
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- TACE (NCT02006030)
- Testing
- ADI-PEG 20, Transarterial chemoembolization
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Polaris Group
Advanced Hepatocellular Carcinoma
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.
- Trial name
- TACE (NCT03905967)
- Testing
- TACE, Lenvatinib
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Chemoembolization (TACE) is used in the majority of advanced hepatocellular carcinomas. Randomized clinical trials indicated that TACE improves overall survival in patients with good liver function (Child-pugh A or B).
- Trial name
- NCT00921531
- Testing
- Thalidomide, TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
In this study, patients with hepatocellular carcinoma were used as the research object to explore the effectiveness and safety of idarubicin hepatic artery perfusion combined with lipiodol embolization, and to preliminarily…
- Trial name
- NCT05053386
- Testing
- Idarubicin Hydrochloride for Injection, Epirubicin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhejiang Cancer Hospital
HepatoCellular Carcinoma
Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term…
- Trial name
- NCT03007225
- Testing
- Trans-arterial chemoembolization (TACE), TACE with Drug Eluting Beads procedure
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT02220088
- Testing
- TAI of FOLFOX, Sorafenib
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
TACE Combined With Penpulimab and Anlotinib for Advanced HCC
The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum interval of the combination of…
- Trial name
- NCT05344924
- Testing
- TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Hepatoma
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially.
- Trial name
- NCT00844883
- Testing
- sorafenib, LC Bead-TACE
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Carcinoma, Hepatocellular, Liver Cell Carcinoma
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic…
- Trial name
- NCT05366829
- Testing
- Tislelizumab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rutgers, The State University of New Jersey
Hepatocellular Carcinoma
Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular Carcinoma
The objective is to evaluate the safety and therapeutic effect of combined hyperthermia and TACE for unresectable HCC
- Trial name
- NCT01817205
- Testing
- TACE with Hyperthermia Treatment
- Where
- 2 sites in Hong Kong
- Volunteers
- 8 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above.
- Conditions
- Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
- Trial name
- NCT04834674
- Testing
- DEB-TACE combined with apatinib and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Liver Neoplasms
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors.
- Trial name
- NCT06261814
- Testing
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- john eisenbrey
Hepatocellular Carcinoma (HCC), Liver Neoplasms
Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
The goal of this observational study is to evaluate changes in selected biomarkers and their potential connection with early radiological outcomes in adult patients with hepatocellular carcinoma (HCC) who are candidates for…
- Trial name
- BLOOD-TACE-P (NCT07378709)
- Where
- Serbia
- Volunteers
- 15 people
- Sponsor
- University of Belgrade
Hepatocellular Carcinoma (HCC)
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
This is an open-label, single-center, single-arm phase Ib clinical trial. The aim of this study is to assess the safety and efficacy of JS014 in combination with Toripalimab and transarterial chemoembolization (TACE) for…
- Trial name
- NCT06882876
- Testing
- JS014 Combined With Toripalimab and TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiangya Hospital of Central South University
Liver Cancer, Liver Neoplasm
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Background: Treatment for liver cancer can include surgery, transplant, and chemotherapy. It can also include other minimally invasive tumor treatments such as transarterial chemoembolization (TACE).
- Conditions
- Liver Cancer, Liver Neoplasm, Hepatocellular Carcinoma, HCC
- Trial name
- NCT02471313
- Testing
- [18F] FMISO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Indication : Hepatocellular carcinoma, maximum size 9 cm, with single or multiple nodes whose total tumor mass can technically be irradiated, non-resectable, and not a candidate for percutaneous therapy with recommended treatment…
- Trial name
- TACERTE (NCT01300143)
- Testing
- TACE, TACE+ RTC
- Where
- 18 sites in France
- Volunteers
- 126 people
- Sponsor
- Nantes University Hospital
HCC - Hepatocellular Carcinoma
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants with incurable/non-metastatic HCC.
- Trial name
- NCT07521852
- Testing
- CVM-1118 + Sintilimab + TACE
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- TaiRx, Inc.
Hepatocellular Carcinoma
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
This is a prospective, multicenter, randomized, open-label phase 3 study evaluating the efficacy and safety of transarterial chemoembolization (TACE) combined with a triple oral cocktail regimen versus TACE combined with targeted…
- Trial name
- Cocktail-001 (NCT07309419)
- Testing
- Apatinib, Camrelizumab, TACE
- Volunteers
- 222 people
- Sponsor
- Shanghai Zhongshan Hospital